Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real

Journal of Pain and Symptom Management

Volumn 41, Issue 1, 2011, Pages 126-139

  Argyriou, Andreas A ^a,b   Assimakopoulos, Konstantinos ^b   Iconomou, Gregoris ^b   Giannakopoulou, Fotini ^b   Kalofonos, Haralabos P ^b  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Chemotherapy; cognitive impairment; diagnosis; incidence; toxicities; treatment

Indexed keywords

CANCER PATIENT; CANCER SURVIVOR; CHEMOTHERAPY; CHEMOTHERAPY INDUCED COGNITIVE IMPAIRMENT; COGNITIVE DEFECT; HUMAN; INCIDENCE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SOLID TUMOR; COGNITION DISORDERS; COMPLICATION; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE BASED MEDICINE; NEOPLASMS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; NEOPLASMS; RISK FACTORS; SURVIVORS; TREATMENT OUTCOME;

EID: 78651279635     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.04.021     Document Type: Review

References (75)

1. C. Sioka, and A.P. Kyritsis Central and peripheral nervous system toxicity of common chemotherapeutic agents Cancer Chemother Pharmacol 63 2009 761 767
2. R.J. Ferguson, and T.A. Ahles Chemotherapy associated cognitive impairment in patients with cancer and cancer survivors Curr Neurol Neurosci Rep 3 2003 215 222
3. A.J. Saykin, T.A. Ahles, and B.C. McDonald Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives Semin Clin Neuropsychiatry 8 2003 201 216
4. C. Anderson-Hanley, M.L. Sherman, R. Riggs, V.B. Agocha, and B.E. Compas Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature J Int Neuropsychol Soc 9 2003 967 982
5. T.A. Ahles, and A.J. Saykin Candidate mechanisms for chemotherapy-induced cognitive changes Nat Rev Cancer 7 2007 192 201
6. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473 3478
7. J. Vardy, J.S. Wefel, T. Ahles, I.F. Tannock, and S.B. Schagen Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop Ann Oncol 19 2008 623 629
8. J. Dietrich, R. Han, Y. Yang, M. Mayer-Pröschel, and M. Noble CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo J Biol 5 2006 22
9. J. Vardy, S. Rourke, and I.F. Tannock Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research J Clin Oncol 25 2007 2455 2463
10. N. Tchen, H.G. Juffs, and F.P. Downie Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer J Clin Oncol 21 2003 4175 4183
11. J. Blasiak, M. Arabski, and R. Krupa Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer Mutat Res 554 2004 139 148
12. M. Valko, D. Leibfritz, and J. Moncol Free radicals and antioxidants in normal physiological functions and human disease Int J Biochem Cell Biol 39 2007 44 84
13. T.M. Wardell, E. Ferguson, and P.F. Chinnery Changes in the human mitochondrial genome after treatment of malignant disease Mutat Res 525 2003 19 27
14. D. Barton, and C. Loprinzi Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible Clin Breast Cancer 3 Suppl 3 2002 S121 S127
15. P. Heras, A.A. Argyriou, and S. Papapetropoulos The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients Eur J Cancer Care (Engl) 14 2005 108 112
16. P.B. Jacobsen, L.L. Garland, and M. Booth-Jones Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy J Pain Symptom Manage 28 2004 7 18
17. J.A. O'Shaughnessy, S.J. Vukelja, and F.A. Holmes Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy Clin Breast Cancer 5 2005 439 446
18. E. Massa, C. Madeddu, M.R. Lusso, G. Gramignano, and G. Mantovani Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy Crit Rev Oncol Hematol 57 2006 175 182
19. G. Iconomou, A. Koutras, and K. Karaivazoglou Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy Eur J Cancer Care (Engl) 17 2008 535 541
20. C.S. Cleeland, G.J. Bennett, and R. Dantzer Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms Cancer 97 2003 2919 2925
21. C.A. Meyers Mood and cognitive disorders in cancer patients receiving cytokine therapy Adv Exp Med Biol 461 1999 75 81
22. N. Tsavaris, C. Kosmas, M. Vadiaka, P. Kanelopoulos, and D. Boulamatsis Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes Br J Cancer 87 2002 21 27
23. C.M. Booth, J. Vardy, and A. Crawley Cognitive impairment associated with chemotherapy for breast cancer: an exploratory case-control study J Clin Oncol 24 Suppl 18 2006 8501 [abstract]
24. J. Vardy, S. Rourke, and J. Galica Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function J Clin Oncol 24 Suppl 18 2006 3623 [abstract]
25. S. Taillibert, D. Voillery, and C. Bernard-Marty Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 19 2007 623 627
26. B.S. Fogel The high sensitivity cognitive screen Int Psychogeriatr 3 1991 273 288
27. C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston, and I.F. Tannock Cognitive function in breast cancer patients receiving adjuvant chemotherapy J Clin Oncol 18 2000 2695 2701
28. J. Vardy, K. Wong, and Q.L. Yi Assessing cognitive function in cancer patients Support Care Cancer 14 2006 1111 1118
29. G. Iconomou, V. Mega, A. Koutras, A.V. Iconomou, and H.P. Kalofonos Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy Cancer 101 2004 404 411
30. V. Shilling, V. Jenkins, and I.S. Trapala The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy Breast Cancer Res Treat 95 2006 125 129
31. S.B. Schagen, F.S. van Dam, and M.J. Muller Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 1999 640 650
32. T.A. Ahles, A.J. Saykin, and W.W. Noll The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy Psychooncology 12 2003 612 619
33. J. Vardy, and I. Tannock Cognitive function after chemotherapy in adults with solid tumours Crit Rev Oncol Hematol 63 2007 183 202
34. J.S. Wefel, R. Lenzi, R.L. Theriault, R.N. Davis, and C.A. Meyers The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial Cancer 100 2004 2292 2299
35. C.E. Jansen, M.J. Dodd, C.A. Miaskowski, G.A. Dowling, and J. Kramer Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide Psychooncology 17 2008 1189 1195
36. K. Hermelink, M. Untch, and M.P. Lux Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study Cancer 109 2007 1905 1913 (Pubitemid 46668557)
37. S.B. Schagen, M.J. Muller, W. Boogerd, G.J. Mellenbergh, and F.S. van Dam Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients J Natl Cancer Inst 98 2006 1742 1745
38. K.J. Vearncombe, M. Rolfe, and M. Wright Predictors of cognitive decline after chemotherapy in breast cancer patients J Int Neuropsychol Soc 15 2009 951 962
39. M.M. Cherrier, S. Aubin, and C.S. Higano Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer Psychooncology 18 2009 237 247
40. C.E. Jansen, C. Miaskowski, M. Dodd, G. Dowling, and J. Kramer A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function Cancer 104 2005 2222 2233
41. M.G. Falleti, A. Sanfilippo, P. Maruff, L. Weih, and K.A. Phillips The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature Brain Cogn 59 2005 60 70
42. A. Stewart, C. Bielajew, B. Collins, M. Parkinson, and E. Tomiak A metaanalysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer Clin Neuropsychol 20 2006 76 89
43. S.B. Schagen, W. Boogerd, and M.J. Muller Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer Acta Oncol 47 2008 63 70
44. D.L. Patrick, S.L. Ferketich, P.S. Frame National Institutes of Health State-of-the-Science Panel National Institutes of Health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue J Natl Cancer Inst 95 2003 1110 1117
45. J.S. Wefel, R. Lenzi, and R. Theriault "Chemobrain" in breast carcinoma?: a prologue Cancer 101 2004 466 475
46. M. Mehlsen, A.D. Pedersen, A.B. Jensen, and R. Zachariae No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy Psychooncology 18 2009 248 257
47. S.A. Castellon, P.A. Ganz, and J.E. Bower Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen J Clin Exp Neuropsychol 26 2004 955 969
48. V. Jenkins, V. Shilling, and G. Deutsch A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 2006 828 834
49. B. Collins, J. Mackenzie, A. Stewart, C. Bielajew, and S. Verma Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study Psychooncology 18 2009 811 821
50. A. Paganini-Hill, and L.J. Clark Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen Breast Cancer Res Treat 64 2000 165 176
51. T. Ernst, L. Chang, and D. Cooray The effects of tamoxifen and estrogen on brain metabolism in elderly women J Natl Cancer Inst 94 2002 592 597
52. V. Shilling, V. Jenkins, L. Fallowfield, and T. Howell The effects of hormone therapy on cognition in breast cancer J Steroid Biochem Mol Biol 86 2003 405 412
53. V.A. Jenkins, L.M. Ambroisine, and L. Atkins Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II) Lancet Oncol 9 2008 953 961
54. E.K. Salminen, R.I. Portin, A. Koskinen, H. Helenius, and M. Nurmi Associations between serum testosterone fall and cognitive function in prostate cancer patients Clin Cancer Res 10 2004 7575 7582
55. H.J. Green, K.I. Pakenham, and B.C. Headley Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial BJU Int 90 2002 427 432
56. T.M. Beer, L.B. Bland, and J.R. Bussiere Testosterone loss and estradiol administration modify memory in men J Urol 175 2006 130 135
57. F. Joly, S.M. Alibhai, and J. Galica Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer J Urol 176 6 pt 1 2006 2443 2447
58. M. Inagaki, E. Yoshikawa, Y. Matsuoka The Breast Cancer Survivors' Brain MRI Database Group Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy Cancer 109 2007 146 156
59. J. Abraham, M.W. Haut, and M.T. Moran Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging Clin Breast Cancer 8 2008 88 91
60. D.H. Silverman, C.J. Dy, and S.A. Castellon Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy Breast Cancer Res Treat 103 2007 303 311
61. S.B. Schagen, H.L. Hamburger, M.J. Muller, W. Boogerd, and F.S. van Dam Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function J Neurooncol 51 2001 159 165
62. D.D. Correa, and T.A. Ahles Neurocognitive changes in cancer survivors Cancer J 14 2008 396 400
63. P.S. Jensen Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting Am J Manag Care 15 5 Suppl 2009 S129 S140
64. H.G. Mar Fan, M. Clemons, and W. Xu A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer Support Care Cancer 16 2008 577 583
65. E.E. Lower, S. Fleishman, and A. Cooper Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial J Pain Symptom Manage 38 2009 650 662
66. O. Minton, P. Stone, A. Richardson, M. Sharpe, and M. Hotopf Drug therapy for the management of cancer related fatigue Cochrane Database Syst Rev 1 2008 CD006704
67. E. Prommer Modafinil: is it ready for prime time? J Opioid Manag 2 2006 130 136
68. S. Kohli, S.G. Fisher, and Y. Tra The effect of modafinil on cognitive function in breast cancer survivors Cancer 115 2009 2605 2616
69. J. Birks, and J. Grimley Evans Ginkgo biloba for cognitive impairment and dementia Cochrane Database Syst Rev 1 2009 CD003120
70. North Central Cancer Treatment Group The use of ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction Available from ClinicalTrials.gov Identifier: NCT00046891. Accessed February 26, 2010
71. B. Winblad, S.E. Black, and A. Homma Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials Curr Med Res Opin 25 2009 2577 2587
72. A. Jatoi, S.P. Kahanic, and S. Frytak Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs Support Care Cancer 13 2005 66 69
73. O.B. Usoro, and S.A. Mousa Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences Crit Rev Food Sci Nutr 50 2010 414 419
74. N.R. Selden, D.R. Gitelman, N. Salamon-Murayama, T.B. Parrish, and M.M. Mesulam Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain Brain 121 1998 2249 2257
75. R.J. Ferguson, T.A. Ahles, and A.J. Saykin Cognitive-behavioral management of chemotherapy-related cognitive change Psychooncology 16 2007 772 777